{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:09:56Z","timestamp":1787616596949,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.1038\/s41416-025-03256-2","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T08:41:52Z","timestamp":1763887312000},"page":"519-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IL-33 released during liver resection facilitates intrahepatic cholangiocarcinoma growth via cytokine secretion in cancer-associated fibroblasts"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-3462","authenticated-orcid":false,"given":"Satoshi","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-3800","authenticated-orcid":false,"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Tomimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-5783","authenticated-orcid":false,"given":"Takehiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Sakaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"3256_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/hep.27687","volume":"61","author":"D Yamada","year":"2015","unstructured":"Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015;61:1627\u201342.","journal-title":"Hepatology"},{"key":"3256_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/OTT.S93629","volume":"10","author":"S Buettner","year":"2017","unstructured":"Buettner S, van Vugt JL, IJzermans J, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131\u201342.","journal-title":"Onco Targets Ther"},{"key":"3256_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Groot Koerkamp B, Do RK, Gonen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122:758\u201365.","journal-title":"Cancer"},{"key":"3256_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol"},{"key":"3256_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.surg.2012.12.005","volume":"153","author":"O Hyder","year":"2013","unstructured":"Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013;153:811\u20138.","journal-title":"Surgery"},{"key":"3256_CR6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1245\/s10434-022-12463-7","volume":"30","author":"L Alaimo","year":"2023","unstructured":"Alaimo L, Moazzam Z, Brown ZJ, Endo Y, Ruzzenente A, Guglielmi A, et al. Application of hazard function to investigate recurrence of intrahepatic cholangiocarcinoma after curative-intent liver resection: a novel approach to characterize recurrence. Ann Surgical Oncol. 2023;30:1340\u20139.","journal-title":"Ann Surgical Oncol"},{"key":"3256_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3389\/fonc.2019.00854","volume":"9","author":"H Yang","year":"2019","unstructured":"Yang H, Wang J, Li Z, Yang Y, Yang L, Zhang Y, et al. Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma. Front Oncol. 2019;9:854.","journal-title":"Front Oncol"},{"key":"3256_CR8","doi-asserted-by":"crossref","unstructured":"Zhang Y, A Esmail, V Mazzaferro, M Abdelrahim. Newest therapies for cholangiocarcinoma: an updated overview of approved treatments with transplant oncology vision. Cancers. 14 (2022).","DOI":"10.3390\/cancers14205074"},{"key":"3256_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003\u201318.","journal-title":"Immunity"},{"key":"3256_CR10","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.str.2009.08.009","volume":"17","author":"A Lingel","year":"2009","unstructured":"Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure. 2009;17:1398\u2013410.","journal-title":"Structure"},{"key":"3256_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/j.1432-2277.2011.01306.x","volume":"24","author":"SM Brunner","year":"2011","unstructured":"Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int. 2011;24:1027\u201339.","journal-title":"Transpl Int"},{"key":"3256_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.it.2016.03.007","volume":"37","author":"M Peine","year":"2016","unstructured":"Peine M, Marek RM, L\u00f6hning M. IL-33 in T Cell Differentiation, Function, and Immune Homeostasis. Trends Immunol. 2016;37:321\u201333.","journal-title":"Trends Immunol"},{"key":"3256_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/cas.14709","volume":"112","author":"S Nagaoka","year":"2021","unstructured":"Nagaoka S, Yamada D, Eguchi H, Yokota Y, Iwagami Y, Asaoka T, et al. The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma. Cancer Sci. 2021;112:347\u201358.","journal-title":"Cancer Sci"},{"key":"3256_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.bbrc.2014.09.106","volume":"453","author":"X Liu","year":"2014","unstructured":"Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, et al. IL-33\/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 2014;453:486\u201392.","journal-title":"Biochem Biophys Res Commun"},{"key":"3256_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/path.4226","volume":"231","author":"SF Chen","year":"2013","unstructured":"Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231:180\u20139.","journal-title":"J Pathol"},{"key":"3256_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2147\/OTT.S155905","volume":"11","author":"Z Yang","year":"2018","unstructured":"Yang Z, Gao X, Wang J, Xu L, Zheng Y, Xu Y. Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells. OncoTargets Ther. 2018;11:843\u20139.","journal-title":"OncoTargets Ther"},{"key":"3256_CR17","doi-asserted-by":"crossref","unstructured":"Joshi RS, Kanugula SS, Sudhir S, Pereira MP, Jain S, Aghi MK. The Role of Cancer-Associated Fibroblasts in Tumor Progression. Cancers. 2021;13.","DOI":"10.3390\/cancers13061399"},{"key":"3256_CR18","first-page":"e268","volume":"25","author":"V Ramos-Vega","year":"2020","unstructured":"Ramos-Vega V, Venegas Rojas B, Donoso Torres W. Immunohistochemical analysis of cancer-associated fibroblasts and podoplanin in head and neck cancer. Med Oral Patol Oral Cir Bucal. 2020;25:e268\u201376.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"3256_CR19","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1245\/s10434-018-6431-8","volume":"25","author":"Y Mukai","year":"2018","unstructured":"Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, et al. Vitamin D supplementation is a promising therapy for pancreatic ductal adenocarcinoma in conjunction with current chemoradiation therapy. Ann Surg Oncol. 2018;25:1868\u201379.","journal-title":"Ann Surg Oncol"},{"key":"3256_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrgastro.2011.222","volume":"9","author":"AE Sirica","year":"2011","unstructured":"Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:44\u201354.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3256_CR21","doi-asserted-by":"publisher","first-page":"956224","DOI":"10.3389\/fimmu.2022.956224","volume":"13","author":"R Zou","year":"2022","unstructured":"Zou R, Jiang Q, Jin T, Chen M, Yao L, Ding H. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer. Front Immunol. 2022;13:956224.","journal-title":"Front Immunol"},{"key":"3256_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-023-01306-3","volume":"9","author":"Z Guo","year":"2023","unstructured":"Guo Z, Zhang H, Fu Y, Kuang J, Zhao B, Zhang L, et al. Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell Death Discov. 2023;9:6.","journal-title":"Cell Death Discov"},{"key":"3256_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579\u201396.","journal-title":"J Exp Med"},{"key":"3256_CR24","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.3390\/cancers13143442","volume":"13","author":"Y-C Lin","year":"2021","unstructured":"Lin Y-C, Huang W-Y, Lee T-Y, Chang Y-M, Chen S-F, Lin Y-S, et al. Interleukin-33-Enhanced CXCR4 Signaling Circuit Mediated by Carcinoma-Associated Fibroblasts Promotes Invasiveness of Head and Neck Cancer. Cancers. 2021;13:3442.","journal-title":"Cancers"},{"key":"3256_CR25","doi-asserted-by":"crossref","unstructured":"Feng C, Kou L, Yin P, Jing Y. Excessive activation of IL\u201133\/ST2 in cancer\u2011associated fibroblasts promotes invasion and metastasis in ovarian cancer. Oncol Lett. 2022;23.","DOI":"10.3892\/ol.2022.13278"},{"key":"3256_CR26","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1245\/s10434-023-13633-x","volume":"30","author":"S Eguchi","year":"2023","unstructured":"Eguchi S, Yamada D, Kobayashi S, Sasaki K, Iwagami Y, Tomimaru Y, et al. Automated analysis for the prevalence of cancer-associated fibroblasts in resected specimens of intrahepatic cholangiocarcinoma is a simple and reliable evaluation system. Ann Surg Oncol. 2023;30:5420\u20138.","journal-title":"Ann Surg Oncol"},{"key":"3256_CR27","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1053\/j.gastro.2005.03.010","volume":"128","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005;128:2054\u201365.","journal-title":"Gastroenterology"},{"key":"3256_CR28","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","volume":"19","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;19:2878\u201380.","journal-title":"Cell Rep"},{"key":"3256_CR29","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/cas.13700","volume":"109","author":"G Shinke","year":"2018","unstructured":"Shinke G, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, et al. Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer. Cancer Sci. 2018;109:2520\u201331.","journal-title":"Cancer Sci"},{"key":"3256_CR30","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1245\/s10434-011-1797-x","volume":"19","author":"D Yamada","year":"2012","unstructured":"Yamada D, Kobayashi S, Yamamoto H, Tomimaru Y, Noda T, Uemura M, et al. Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Ann Surg Oncol. 2012;19:S355\u201364.","journal-title":"Ann Surg Oncol"},{"key":"3256_CR31","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1002\/cam4.1704","volume":"7","author":"M Sha","year":"2018","unstructured":"Sha M, Jeong S, Qiu BJ, Tong Y, Xia L, Xu N, et al. Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma. Cancer Med. 2018;7:4665\u201377.","journal-title":"Cancer Med"},{"key":"3256_CR32","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.7150\/jca.20324","volume":"8","author":"J Chen","year":"2017","unstructured":"Chen J, Yang P, Xiao Y, Zhang Y, Liu J, Xie D, et al. Overexpression of \u03b1-sma-positive fibroblasts (CAFs) in nasopharyngeal carcinoma predicts poor prognosis. J Cancer. 2017;8:3897\u2013902.","journal-title":"J Cancer"},{"key":"3256_CR33","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cam4.2939","volume":"9","author":"X Cong","year":"2020","unstructured":"Cong X, Zhang Y, Zhu Z, Li S, Yin X, Zhai Z, et al. CD66b + neutrophils and \u03b1-SMA + fibroblasts predict clinical outcomes and benefits from postoperative chemotherapy in gastric adenocarcinoma. Cancer Med. 2020;9:2761\u201373.","journal-title":"Cancer Med"},{"key":"3256_CR34","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.18632\/oncotarget.14374","volume":"8","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Sakakura K, Kudo T, Toyoda M, Kaira K, Oyama T, et al. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget. 2017;8:8633\u201347.","journal-title":"Oncotarget"},{"key":"3256_CR35","doi-asserted-by":"publisher","first-page":"1189527","DOI":"10.3389\/fmolb.2023.1189527","volume":"10","author":"GG Reivan Ortiz","year":"2023","unstructured":"Reivan Ortiz GG, Ciongradi CI, Chaitanya M, Narayanan J, Mohany M, Al-Rejaie SS, et al. Identification of novel candidate targets for suppressing ovarian cancer progression through IL-33\/ST2 axis components using the system biology approach. Front Mol Biosci. 2023;10:1189527.","journal-title":"Front Mol Biosci"},{"key":"3256_CR36","doi-asserted-by":"crossref","unstructured":"Gu D, Zhao X, Song J, Xiao J, Zhang L, Deng G, et al. Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma. Front Immunol. 2024;15.","DOI":"10.3389\/fimmu.2024.1374967"},{"key":"3256_CR37","first-page":"531","volume":"10","author":"G Shinke","year":"2019","unstructured":"Shinke G, Yamada D, Eguchi H, Iwagami Y, Akita H, Asaoka T, et al. The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma. Mol Clin Oncol. 2019;10:531\u201340.","journal-title":"Mol Clin Oncol"},{"key":"3256_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"3256_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/archsurg.2011.116","volume":"146","author":"JC Hong","year":"2011","unstructured":"Hong JC, Jones CM, Duffy JP. Comparative analysis of resection and liver transplantation for intrahepatic and Hilar cholangiocarcinoma. Arch Surg. 2011;146:683.","journal-title":"Arch Surg"},{"key":"3256_CR40","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.3390\/cancers13133281","volume":"13","author":"MR Choi","year":"2021","unstructured":"Choi MR, Sosman JA, Zhang B. The Janus face of IL-33 signaling in tumor development and immune escape. Cancers. 2021;13:3281.","journal-title":"Cancers"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03256-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:55:16Z","timestamp":1769615716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03256-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,8]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03256-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. has received honoraria from AstraZeneca, Novartis, Olympus, and Taiho. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}